Agomab

Agomab is emerging as a significant player in the Biotechnology sector, established in 2017 and headquartered in Belgium. The company leverages its deep expertise in growth factor biology to innovate treatments aimed at resolving fibrosis, repairing tissue structures, and restoring organ functionality.

Agomab's core mission is to develop a broad clinical pipeline targeting severe organ failure and fibrotic diseases, demonstrating disease-modifying potential. By merging groundbreaking scientific insights with robust drug development, the company is poised to address unmet medical needs through novel therapeutics.

In its latest funding round, Series D, Agomab secured €82.10M on 25 October 2024, attracting substantial interest from prominent investors including Invus, Asabys Partners, and Sanofi. This capital influx aims to accelerate the company's ambitious research and development efforts, positioning Agomab for significant growth in the healthcare and wellness sectors.